Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Rapoport, Bernardo Leon![]() |
|
dc.contributor.author | Theron, Annette J.![]() |
|
dc.contributor.author | Vorobiof, Daniel A.![]() |
|
dc.contributor.author | Langenhoven, Lizanne![]() |
|
dc.contributor.author | Hall, Jacqueline M.![]() |
|
dc.contributor.author | Van Eeden, Ronwyn I.![]() |
|
dc.contributor.author | Smit, Teresa![]() |
|
dc.contributor.author | Chan, Sze-Wai![]() |
|
dc.contributor.author | Botha, Michael C.![]() |
|
dc.contributor.author | Raats, Johann I.![]() |
|
dc.contributor.author | De Necker, Margriet![]() |
|
dc.contributor.author | Anderson, Ronald![]() |
|
dc.date.accessioned | 2021-08-27T05:34:32Z | |
dc.date.available | 2021-08-27T05:34:32Z | |
dc.date.issued | 2020-06 | |
dc.description.abstract | AIM: We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab. MATERIALS & METHODS: This was a multicenter, noninterventional, retrospective data analysis, involving five oncology centers. RESULTS: Patients with prenivolumab NLR values of <5 and ≥5 had respective median overall survival (OS) values of 14.5 and 7.02 months (p = 0.0026). Patients with ≤2 and >2 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (p = 0.0174). A Cox multiple regression model revealed baseline NLR ≥5 as the only variable significantly associated with decreased OS (p < 0.0447). CONCLUSION: Pretreatment elevated NLR values are associated with poor outcomes in patients with recurrent metastatic non-small-cell lung cancer treated with nivolumab. | en_ZA |
dc.description.department | Immunology | en_ZA |
dc.description.librarian | hj2021 | en_ZA |
dc.description.uri | http://www.futuremedicine.com/loi/lmt | en_ZA |
dc.identifier.citation | Rapoport, B.L., Theron, A.J., Vorobiof, D.A., et al. 2020, ' Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer', Lung Cancer Management, vol. 9, no. 3, art. LMT37, pp. 1-12. | en_ZA |
dc.identifier.issn | 1758-1966 (print) | |
dc.identifier.issn | 1758-1974 (online) | |
dc.identifier.other | 10.2217/lmt-2020-0014 | |
dc.identifier.uri | http://hdl.handle.net/2263/81521 | |
dc.language.iso | en | en_ZA |
dc.publisher | MDPI | en_ZA |
dc.rights | © 2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). | en_ZA |
dc.subject | Nivolumab | en_ZA |
dc.subject | PD-1 inhibitor | en_ZA |
dc.subject | Pretherapy measurement | en_ZA |
dc.subject | Neutrophil/lymphocyte ratio (NLR) | en_ZA |
dc.subject | Non-small cell lung cancer (NSCLC) | en_ZA |
dc.title | Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer | en_ZA |
dc.type | Article | en_ZA |